RELAPSED

作品数：95被引量：150H指数：7
导出分析报告
相关领域：医药卫生农业科学更多>>
相关作者：关涛苏丽萍马莉赵瑾王晶荣更多>>
相关机构：上海市第一人民医院绍兴文理学院绍兴市人民医院浙江省人民医院更多>>
相关期刊：《Asian Journal of Andrology》《Journal of Integrative Medicine》《Open Journal of Blood Diseases》《Cellular & Molecular Immunology》更多>>
相关基金：国家自然科学基金北京市自然科学基金广东省自然科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
选择条件：
  • 期刊=Signal Transduction and Targeted Therapyx
共 条 记 录，以下是1-6
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Sintilimab(anti-PD-1 antibody)plus chidamide(histone deacetylase inhibitor)in relapsed or refractory extranodal natural killer T-cell lymphoma(SCENT):a phase Ⅰb/Ⅱ study被引量：2
《Signal Transduction and Targeted Therapy》2024年第6期2765-2773,共9页Yan Gao Haixia He Xueping Li Liling Zhang Wei Xu Ru Feng Wenyu Li Yin Xiao Xinxiu Liu Yu Chen Xiaoxiao Wang Bing Bai Huijing Wu Qingqing Cai Zhiming Li Jibin Li Suxia Lin Yanxia He Liqin Ping Cheng Huang Jiaying Mao Xiujin Chen Baitian Zhao Huiqiang Huang 
supported by the National Natural Science Foundation of China(grant numbers 82170188 and 81970176);Guangdong Basic and Applied Basic Research Foundation(grant number 2021A1515110012).
Anti-PD-1 antibodies are a favorable treatment for relapsed or refractory extranodal natural killer T cell lymphoma(RR-ENKTL),however,the complete response(CR)rate and the duration of response(DOR)need to be improved....
关键词：KILLER LYMPHOMA doses 
Phase II study of novel orally PI3Kα/δinhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma被引量：2
《Signal Transduction and Targeted Therapy》2024年第5期2193-2201,共9页Huaqing Wang Jifeng Feng Yanyan Liu Zhengzi Qian Da Gao Xuehong Ran Hui Zhou Lihong Liu Binghua Wang Meiyun Fang Hebing Zhou Zhenqian Huang Shi Tao Zhuowen Chen Liping Su Hang Su Yu Yang Xiaobao Xie Huijing Wu Ping Sun Guoyu Hu Aibin Liang Zhiming Li 
This study was sponsored by Chia Tai Tianqing Pharmaceutical Group Co.,Ltd.(Nanjing,China)and was supported by grants from National Natural Science Foundation of China(Grant Number,81872902,82073917,and 82070206);National Natural Science Foundation of Guangdong Province(Grant Number,2023A1515011525);The Lymphoma Research Fund of China Anti-Cancer Association,and the Sun Yat-sen University Cancer Center Clinical Research 308 Program(Grant Number,2014-fxy-106 and 2016-fxy-079);Tianjin Key Medical Discipline(Specialty)Construction Project(Grant Number,TJYXZDXK-053B).
This registration study assessed clinical outcomes of TQ-B3525,the dual phosphatidylinositol-3-kinase(PI3K)α/δinhibitor,in relapsed and/or refractory follicular lymphoma(R/R FL).This phase II study(ClinicalTrials.go...
关键词：LYMPHOMA assessed initiated 
Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma被引量：1
《Signal Transduction and Targeted Therapy》2023年第10期4978-4984,共7页Weiping Liu Ningjing Lin Xinqin Feng Yan Xie Chong You Xiaohua Zhou Yuqin Song Jun Zhu 
This study was supported by the Clinical Research Fund for Distinguished Young Scholars of Beijing Cancer Hospital(Grant No.QNJJ202106);Beijing Xisike Clinical Oncology Research Foundation(Grant No.Y-HS202202-0104 and Y-Young2023-0286);National Natural Science Foundation of China(Grant No.81972807).
Anti-programmed cell death-1(anti-PD-1)therapies have shown a favorable efficacy and good tolerance for relapsed or refractory(r/r)classical Hodgkin lymphoma(cHL).However,there are limited data on long-term outcomes a...
关键词：PATIENTS LYMPHOMA RELAPSE 
Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders:phase 1 trial interim results被引量：14
《Signal Transduction and Targeted Therapy》2023年第2期683-691,共9页Chuan Qin Dai-Shi Tian Luo-Qi Zhou Ke Shang Liang Huang Ming-Hao Dong Yun-Fan You Jun Xiao Ying Xiong Wen Wang Hao Pang Jing-Jing Guo Song-Bai Cai Di Wang Chun-Rui Li Min Zhang Bi-Tao Bu Wei Wang 
Chimeric antigen receptor(CAR)T-cell therapy that targets B-cell maturation antigen(BCMA)have great potentials in autoimmune diseases and could be novel therapeutics for relapsed/refractory neuromyelitis optica spectr...
关键词：AQP4 BCMA INFUSION 
Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma:5-years follow-up results of the phase I and IIa trials被引量：1
《Signal Transduction and Targeted Therapy》2017年第1期85-88,共4页Wen-ying Zhang Yang Liu Yao Wang Chun-meng Wang Qing-ming Yang Hong-li Zhu Wei-dong Han 
This study was supported by grants from the National Natural Science Foundation of China(No.81402566);the grants the Science and Technology Planning Project of Beijing City(No.Z151100003915076 to WDH);the National Key Research and Development Program of China(No.2016YFC1303501 and 2016YFC1303504 to WDH).
For refractory or relapsed(r/r)B-cell non-Hodgkin lymphoma(NHL),the response rates to conventional salvage chemotherapy are 27–44%.1 Chimeric antigen receptors(CARs)efficiently redirect T-cell specificity and cytotox...
关键词：LYMPHOMA SPECIFICITY chemotherapy 
Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma:an early phase IIa trial report被引量：12
《Signal Transduction and Targeted Therapy》2016年第1期131-139,共9页Wen-ying Zhang Yao Wang Ye-lei Guo Han-ren Dai Qing-ming Yang Ya-jing Zhang Yan Zhang Mei-xia Chen Chun-meng Wang Kai-chao Feng Su-xia Li Yang Liu Feng-xia Shi Can Luo Wei-dong Han 
This study was supported by the grants from the National Natural Science Foundation of China(Nos.31270820,81230061,81121004 and 81402566);was partially supported by a grant from the National Basic Science and Development Programme of China(Nos.2012CB518103,2012AA020502 and 2013BAI01B00).
Patients with relapsed or refractory non-Hodgkin lymphoma have a dismal prognosis.Chimeric Antigen Receptor(CAR)-modified T cells(CART cells)that targeted CD20 were effective in a phase I clinical trial for patients w...
关键词：PATIENTS LYMPHOMA ANTIGEN 
全选清除导出
共1页<1>
检索报告 对象比较 聚类工具 使用帮助 返回顶部